RESUMO
No abstract available.
Assuntos
Camundongos , Animais , Transporte Biológico/fisiologia , Transporte Biológico/efeitos dos fármacos , Cólera/metabolismo , Diglicerídeos/farmacologia , Células Epiteliais/virologia , Células Epiteliais/microbiologia , Células Epiteliais/metabolismo , Escherichia coli , Infecções por Escherichia coli/metabolismo , Estrenos/farmacologia , Técnicas In Vitro , Indóis/farmacologia , Influenza Humana/metabolismo , Mucosa Intestinal/citologia , Maleimidas/farmacologia , Inibidores de Fosfodiesterase/farmacologia , Pirrolidinonas/farmacologia , Mucosa Respiratória/citologia , Canais de Sódio/metabolismo , Estaurosporina/farmacologia , Vibrio choleraeRESUMO
Two important issue regarding the use of immunization to control infections and malignancies in the futureare: 1) the need to render poorly immunogenic, often highly purified, antigens more effective; and 2) the desire to direct the immune response in specific ways to achieve the most relevant response for each disease. The first issue can be solved by a broad range of vaccine adjuvants. The second requires careful selection among the adjuvants to allow directing of the immune response in the most appropriate manner. For exemple, in different settings expansion of a B cell response, cytotoxic T cell response, or enhancement of either a Th1 or Th2 subset response may be desired. These goals are accomplished by the use of several newly developed non-cytokine adjuvants, or by direct injection of the relevant cytokines. Some non-cytokine molecular adjuvants and cytokines used as adjuvants have already been proven effective in animal models and/or in clinical trials. Here, we review the present state of art in the use of vaccine adjuvants for control of various infections diseases.